Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 6/20 | 0.62 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.33 |
| ▸ | MPO | P05164 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | HASPIN | Q8TF76 | 2/20 | 0.30 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.30 |
| ▸ | CDK9 | P50750 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16610432 | 0.85 | CSNK2A1 (0.44) | CSNK2A1GPR84MPOSLC6A4CHRNB2 | |
| SCHEMBL16610430 | 0.79 | CSNK2A1 (0.36) | CSNK2A1GPR84CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL31609637 | 0.76 | HTR2C (0.47) | CSNK2A1GPR84MPOSLC6A4CHRNB2 | |
| SCHEMBL18080755 | 0.76 | HTR2C (0.47) | CSNK2A1GPR84MPOSLC6A4CHRNB2 | |
| SCHEMBL16610353 | 0.75 | MTNR1A (0.35) | CSNK2A1GPR84CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL16610253 | 0.75 | CYP2D6 (0.49) | CSNK2A1MPOSLC6A4 | |
| SCHEMBL18080754 | 0.75 | CSNK2A1 (0.33) | CSNK2A1GPR84CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL29354243 | 0.74 | CSNK2A1 (0.77) | CSNK2A1GPR84SLC6A4CHRNB2CHRNA7 | |
| SCHEMBL6029334 | 0.74 | CSNK2A1 (0.77) | CSNK2A1GPR84SLC6A4CHRNB2CHRNA7 | |
| SCHEMBL20476417 | 0.74 | HTR1A (0.42) | MPOSLC6A4CHRNB2CHRNA7CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3071566-B1 | NEW 1-(4-PYRIMIDINYL)-1H-PYRROLO[3,2-C]PYRIDINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-15 | — | — | EP | disclosed |
| US-10005773-B2 | 1-(4-pyrimidinyl)-1H-pyrrolo[3,2-c]pyridine derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-26 | — | — | US | disclosed |
| US-10005773-B2 | 1-(4-pyrimidinyl)-1H-pyrrolo[3,2-c]pyridine derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-26 | — | — | US | disclosed |
| US-20160257679-A1 | NEW 1-(4-PYRIMIDINYL)-1H-PYRROLO[3,2-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS | ARGENTA DISCOVERY 2009 LIMITED (GB) | 2016-09-08 | — | — | US | disclosed |
| US-20160257679-A1 | NEW 1-(4-PYRIMIDINYL)-1H-PYRROLO[3,2-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS | ARGENTA DISCOVERY 2009 LIMITED (GB) | 2016-09-08 | — | — | US | disclosed |
| WO-2015044267-A1 | NEW 1-(4-PYRIMIDINYL)-1H-PYRROLO[3,2-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005773-B2 | 1-(4-pyrimidinyl)-1H-pyrrolo[3,2-c]pyridine derivatives as NIK inhibitors | MAP3K14, MAP3K15, MAP3K12 | CSNK2A1 710/4885GPR84 3626/4885MPO 1207/4885 |
| US-20160257679-A1 | NEW 1-(4-PYRIMIDINYL)-1H-PYRROLO[3,2-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS | MAP3K14, MAP3K15, MAP3K12 | CSNK2A1 628/4885GPR84 3508/4885MPO 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.